Rafael Holdings Inc - Ordinary Shares - Class B
RFL
Get informed when a big investor buys or sells
+ FollowMarket Cap$110.62M
Close$
$0.42
81.2% downside
Current Fair Value
81.2% downsideOvervalued by 81.2% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $110.62 Million |
|---|---|
| Enterprise Value | $80.73 Million |
| Dividend Yield | $0.04 (-) |
| Earnings per Share | $-1.04 |
| Beta | 0.33 |
| Outstanding Shares | 51,229,576 |
Return
| Return on Equity | -43.18% |
|---|---|
| Return on Assets | -35.39% |
| Return on Invested Capital | -40.20% |
Valuation & Multiples
| P/E Ratio | -3.16 |
|---|---|
| PEG | 27.35 |
| Price to Sales | - |
| Price to Book Ratio | 2.24 |
| Enterprise Value to Revenue | 82.38 |
| Enterprise Value to EBIT | -2.48 |
| Enterprise Value to Net Income | -3 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0.01 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
June 15, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
October 28, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | 144,900▲ 2.77% |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 7.60%▲ 0.75% |
|---|---|
| Total Invested | $12.75M▲ 190.62% |
| Investors Holding | 44▲ 2.00% |
ESG Score
No data
About Rafael Holdings Inc
57 employeesRafael Holdings is focused on development of novel cancer therapies. The Company is a significant investor in two clinical stage oncology companies, Rafael Pharmaceuticals, Inc. and LipoMedix Pharmaceuticals Ltd. Through its wholly own...